<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02471261</url>
  </required_header>
  <id_info>
    <org_study_id>ESR-14-10146</org_study_id>
    <nct_id>NCT02471261</nct_id>
  </id_info>
  <brief_title>Elastography as Gouty Arthropathy Outcome (EGO)</brief_title>
  <official_title>Elastography as Gouty Arthropathy Outcome (EGO), a Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arthritis &amp; Rheumatism Associates, P.C.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arthritis &amp; Rheumatism Associates, P.C.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Elastography as Gouty Arthropathy Outcome (EGO), a pilot study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pilot study to assess 10 subjects with tophaceous gout on urate lowering therapy or about to&#xD;
      begin urate lowering therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Elastography as Gouty Arthropathy Outcome (EGO), a pilot study</measure>
    <time_frame>1 year</time_frame>
    <description>Observational trial to measure gouty arthritis changes in subject taking urate lowering therapies</description>
  </primary_outcome>
  <enrollment type="Actual">10</enrollment>
  <condition>Gout</condition>
  <eligibility>
    <study_pop>
      <textblock>
        A pilot study to assess 10 subjects with tophaceous gout on urate lowering therapy or about&#xD;
        to begin urate lowering therapy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects who are at least 18 years of age but younger than or equal to 99 years of&#xD;
             age.&#xD;
&#xD;
          2. Subjects with gouty arthritis as determined by the ACR 1977 classification criteria&#xD;
             for gouty arthritis.&#xD;
&#xD;
          3. Subjects with one palpable tophus detectable by one of the three clinical parameters&#xD;
             described.&#xD;
&#xD;
             -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who are not eligible for urate lowering treatment or show a hypersensitivity&#xD;
             to these drugs or class of compounds.&#xD;
&#xD;
          2. Subjects with significant cardiovascular, neuropsychiatric, hematologic, hepatic,&#xD;
             renal or endocrine dysfunction who in the opinion of the principal investigator are&#xD;
             unfit for participation in a clinical trial.&#xD;
&#xD;
          3. Subjects for which the clinical and laboratory assessment would provide undue&#xD;
             discomfort and / or are contraindicated.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Center for Rheumatology and Bone Research</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 11, 2015</study_first_submitted>
  <study_first_submitted_qc>June 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2015</study_first_posted>
  <last_update_submitted>October 22, 2020</last_update_submitted>
  <last_update_submitted_qc>October 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

